Does the media favor SANA or NAMS?

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.31 beat NewAmsterdam Pharma's score of 0.43 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive NewAmsterdam Pharma 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, SANA or TLX?

Telix Pharmaceuticals has higher revenue and earnings than Sana Biotechnology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Telix Pharmaceuticals $803.79M 4.50 -$7.12M N/A N/A

Is SANA or TLX more profitable?

Telix Pharmaceuticals' return on equity of 0.00% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Telix Pharmaceuticals N/A N/A N/A

Does the media favor SANA or TLX?

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 3 mentions for Telix Pharmaceuticals and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.31 beat Telix Pharmaceuticals' score of 0.62 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Telix Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SANA or ARQT?

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.31 beat Arcutis Biotherapeutics' score of 0.89 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Arcutis Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation & earnings, DYN or SANA?

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyne Therapeutics N/A N/A -$446.21M -$3.22 N/A Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A

Is DYN or SANA more profitable?

Dyne Therapeutics' return on equity of -58.28% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Dyne Therapeutics N/A -58.28% -46.77% Sana Biotechnology N/A -108.01% -40.68%

Does the media refer more to DYN or SANA?

In the previous week, Dyne Therapeutics had 10 more articles in the media than Sana Biotechnology. MarketBeat recorded 12 mentions for Dyne Therapeutics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.31 beat Dyne Therapeutics' score of 0.02 indicating that Sana Biotechnology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyne Therapeutics 1 Very Positive mention(s) 4 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Sana Biotechnology 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, SANA or GPCR?

Structure Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sana Biotechnology N/A N/A -$244.17M -$0.93 N/A Structure Therapeutics N/A N/A -$141.20M -$0.87 N/A

Is SANA or GPCR more profitable?

Structure Therapeutics' return on equity of -24.91% beat Sana Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Sana Biotechnology N/A -108.01% -40.68% Structure Therapeutics N/A -24.91% -23.67%

Sana Biotechnology (SANA) Competitors

$3.42 0.00 (0.00%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$3.52 +0.10 (+2.92%)

As of 05:45 AM Eastern

Compare

SANA vs. NAMS, TLX, ARQT, DYN, and GPCR

Should you buy Sana Biotechnology stock or one of its competitors? MarketBeat compares Sana Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sana Biotechnology include NewAmsterdam Pharma (NAMS), Telix Pharmaceuticals (TLX), Arcutis Biotherapeutics (ARQT), Dyne Therapeutics (DYN), and Structure Therapeutics (GPCR). These companies are all part of the "pharmaceutical products" industry.

How does Sana Biotechnology compare to NewAmsterdam Pharma?

Sana Biotechnology (NASDAQ:SANA) and NewAmsterdam Pharma (NASDAQ:NAMS) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, risk, earnings, analyst recommendations, institutional ownership, valuation and media sentiment.

Sana Biotechnology presently has a consensus price target of $9.50, indicating a potential upside of 177.78%. NewAmsterdam Pharma has a consensus price target of $48.60, indicating a potential upside of 46.21%. Given Sana Biotechnology's higher probable upside, research analysts plainly believe Sana Biotechnology is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Sana Biotechnology has a beta of 2.14, suggesting that its share price is 114% more volatile than the broader market. Comparatively, NewAmsterdam Pharma has a beta of 0.07, suggesting that its share price is 93% less volatile than the broader market.

In the previous week, NewAmsterdam Pharma had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for NewAmsterdam Pharma and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.31 beat NewAmsterdam Pharma's score of 0.43 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NewAmsterdam Pharma	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

NewAmsterdam Pharma has higher revenue and earnings than Sana Biotechnology. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
NewAmsterdam Pharma	$22.50M	172.70	-$203.82M	-$1.79	N/A

88.2% of Sana Biotechnology shares are held by institutional investors. Comparatively, 89.9% of NewAmsterdam Pharma shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Comparatively, 12.7% of NewAmsterdam Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Sana Biotechnology has a net margin of 0.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%

Summary

NewAmsterdam Pharma beats Sana Biotechnology on 9 of the 16 factors compared between the two stocks.

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Sana Biotechnology (NASDAQ:SANA) and Telix Pharmaceuticals (NASDAQ:TLX) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, dividends, profitability, valuation, institutional ownership, risk, earnings and analyst recommendations.

88.2% of Sana Biotechnology shares are held by institutional investors. 25.4% of Sana Biotechnology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Telix Pharmaceuticals' return on equity of 0.00% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Telix Pharmaceuticals	N/A	N/A	N/A

Telix Pharmaceuticals has higher revenue and earnings than Sana Biotechnology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Telix Pharmaceuticals	$803.79M	4.50	-$7.12M	N/A	N/A

Sana Biotechnology presently has a consensus target price of $9.50, suggesting a potential upside of 177.78%. Telix Pharmaceuticals has a consensus target price of $21.13, suggesting a potential upside of 98.17%. Given Sana Biotechnology's higher possible upside, equities analysts clearly believe Sana Biotechnology is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Telix Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78

Sana Biotechnology has a beta of 2.14, suggesting that its stock price is 114% more volatile than the broader market. Comparatively, Telix Pharmaceuticals has a beta of -0.1, suggesting that its stock price is 110% less volatile than the broader market.

In the previous week, Telix Pharmaceuticals had 1 more articles in the media than Sana Biotechnology. MarketBeat recorded 3 mentions for Telix Pharmaceuticals and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.31 beat Telix Pharmaceuticals' score of 0.62 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Telix Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Telix Pharmaceuticals beats Sana Biotechnology on 7 of the 13 factors compared between the two stocks.

How does Sana Biotechnology compare to Arcutis Biotherapeutics?

Sana Biotechnology (NASDAQ:SANA) and Arcutis Biotherapeutics (NASDAQ:ARQT) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, risk, media sentiment, valuation and earnings.

Sana Biotechnology has a net margin of 0.00% compared to Arcutis Biotherapeutics' net margin of -0.57%. Arcutis Biotherapeutics' return on equity of -1.41% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Arcutis Biotherapeutics	-0.57%	-1.41%	-0.59%

Arcutis Biotherapeutics has higher revenue and earnings than Sana Biotechnology. Arcutis Biotherapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Arcutis Biotherapeutics	$376.07M	8.98	-$16.14M	-$0.03	N/A

Sana Biotechnology presently has a consensus price target of $9.50, suggesting a potential upside of 177.78%. Arcutis Biotherapeutics has a consensus price target of $34.00, suggesting a potential upside of 25.93%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, equities research analysts clearly believe Sana Biotechnology is more favorable than Arcutis Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Arcutis Biotherapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

88.2% of Sana Biotechnology shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by insiders. Comparatively, 9.4% of Arcutis Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Arcutis Biotherapeutics had 2 more articles in the media than Sana Biotechnology. MarketBeat recorded 4 mentions for Arcutis Biotherapeutics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.31 beat Arcutis Biotherapeutics' score of 0.89 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Arcutis Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sana Biotechnology has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Arcutis Biotherapeutics has a beta of 1.52, indicating that its share price is 52% more volatile than the broader market.

Summary

Sana Biotechnology beats Arcutis Biotherapeutics on 9 of the 15 factors compared between the two stocks.

How does Sana Biotechnology compare to Dyne Therapeutics?

Dyne Therapeutics (NASDAQ:DYN) and Sana Biotechnology (NASDAQ:SANA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, dividends, profitability, earnings, valuation, institutional ownership, analyst recommendations and media sentiment.

Dyne Therapeutics' return on equity of -58.28% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyne Therapeutics	N/A	-58.28%	-46.77%
Sana Biotechnology	N/A	-108.01%	-40.68%

Dyne Therapeutics has a beta of 1.09, indicating that its stock price is 9% more volatile than the broader market. Comparatively, Sana Biotechnology has a beta of 2.14, indicating that its stock price is 114% more volatile than the broader market.

Dyne Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyne Therapeutics	N/A	N/A	-$446.21M	-$3.22	N/A
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A

In the previous week, Dyne Therapeutics had 10 more articles in the media than Sana Biotechnology. MarketBeat recorded 12 mentions for Dyne Therapeutics and 2 mentions for Sana Biotechnology. Sana Biotechnology's average media sentiment score of 1.31 beat Dyne Therapeutics' score of 0.02 indicating that Sana Biotechnology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyne Therapeutics	1 Very Positive mention(s)	4 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sana Biotechnology	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.7% of Dyne Therapeutics shares are owned by institutional investors. Comparatively, 88.2% of Sana Biotechnology shares are owned by institutional investors. 9.5% of Dyne Therapeutics shares are owned by insiders. Comparatively, 25.4% of Sana Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Dyne Therapeutics currently has a consensus price target of $34.17, indicating a potential upside of 63.16%. Sana Biotechnology has a consensus price target of $9.50, indicating a potential upside of 177.78%. Given Sana Biotechnology's higher probable upside, analysts clearly believe Sana Biotechnology is more favorable than Dyne Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyne Therapeutics	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.86
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Sana Biotechnology beats Dyne Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Sana Biotechnology compare to Structure Therapeutics?

Sana Biotechnology (NASDAQ:SANA) and Structure Therapeutics (NASDAQ:GPCR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Structure Therapeutics is trading at a lower price-to-earnings ratio than Sana Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.93	N/A
Structure Therapeutics	N/A	N/A	-$141.20M	-$0.87	N/A

In the previous week, Sana Biotechnology had 1 more articles in the media than Structure Therapeutics. MarketBeat recorded 2 mentions for Sana Biotechnology and 1 mentions for Structure Therapeutics. Structure Therapeutics' average media sentiment score of 1.87 beat Sana Biotechnology's score of 1.31 indicating that Structure Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Sana Biotechnology	Positive
Structure Therapeutics	Very Positive

Sana Biotechnology has a beta of 2.14, indicating that its share price is 114% more volatile than the broader market. Comparatively, Structure Therapeutics has a beta of -1.35, indicating that its share price is 235% less volatile than the broader market.

Sana Biotechnology presently has a consensus price target of $9.50, suggesting a potential upside of 177.78%. Structure Therapeutics has a consensus price target of $110.55, suggesting a potential upside of 122.38%. Given Sana Biotechnology's higher possible upside, analysts plainly believe Sana Biotechnology is more favorable than Structure Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Structure Therapeutics	2 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	3 Strong Buy rating(s)	2.89

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 91.8% of Structure Therapeutics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Comparatively, 5.5% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Structure Therapeutics' return on equity of -24.91% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-108.01%	-40.68%
Structure Therapeutics	N/A	-24.91%	-23.67%

Summary

Structure Therapeutics beats Sana Biotechnology on 9 of the 14 factors compared between the two stocks.

Get Sana Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SANA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SANA vs. The Competition

Export

Metric	Sana Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$951.75M	$3.62B	$6.83B	$12.17B
Dividend Yield	N/A	2.21%	2.66%	6.11%
P/E Ratio	-3.68	21.75	25.89	24.17
Price / Sales	N/A	334.18	547.76	101.00
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	5.70	8.31	10.75	6.38
Net Income	-$244.17M	$23.92M	$3.58B	$337.00M
7 Day Performance	1.79%	1.93%	1.97%	-0.20%
1 Month Performance	3.64%	-0.41%	-0.24%	-1.40%
1 Year Performance	21.71%	65.22%	34.39%	27.76%

Sana Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SANA Sana Biotechnology	2.6311 of 5 stars	$3.42 flat	$9.50 +177.8%	+21.7%	$951.75M	N/A	N/A	380	News Coverage Positive News Gap Down High Trading Volume
NAMS NewAmsterdam Pharma	2.4179 of 5 stars	$30.82 +3.3%	$48.60 +57.7%	+79.0%	$3.49B	$22.50M	N/A	4	News Coverage Positive News
TLX Telix Pharmaceuticals	4.5796 of 5 stars	$10.00 -0.9%	$21.13 +111.3%	-33.4%	$3.42B	$803.79M	N/A	1,184	Gap Up
ARQT Arcutis Biotherapeutics	3.3247 of 5 stars	$26.66 +1.7%	$34.00 +27.5%	+96.5%	$3.28B	$376.07M	N/A	150
DYN Dyne Therapeutics	2.549 of 5 stars	$20.87 +5.4%	$33.85 +62.2%	+118.8%	$3.27B	N/A	N/A	100	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SANA) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sana Biotechnology (SANA) Competitors

SANA vs. NAMS, TLX, ARQT, DYN, and GPCR

How does Sana Biotechnology compare to NewAmsterdam Pharma?

Summary

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Summary

How does Sana Biotechnology compare to Arcutis Biotherapeutics?

Summary

How does Sana Biotechnology compare to Dyne Therapeutics?

Summary

How does Sana Biotechnology compare to Structure Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sana Biotechnology (SANA) Competitors

SANA vs. NAMS, TLX, ARQT, DYN, and GPCR

How does Sana Biotechnology compare to NewAmsterdam Pharma?

Do analysts prefer SANA or NAMS?

Which has more risk & volatility, SANA or NAMS?

Does the media favor SANA or NAMS?

Which has higher valuation & earnings, SANA or NAMS?

Do institutionals and insiders believe in SANA or NAMS?

Is SANA or NAMS more profitable?

Summary

How does Sana Biotechnology compare to Telix Pharmaceuticals?

Do insiders & institutionals have more ownership in SANA or TLX?

Is SANA or TLX more profitable?

Which has higher valuation and earnings, SANA or TLX?

Do analysts rate SANA or TLX?

Which has more risk and volatility, SANA or TLX?

Does the media favor SANA or TLX?

Summary

How does Sana Biotechnology compare to Arcutis Biotherapeutics?

Is SANA or ARQT more profitable?

Which has preferable valuation & earnings, SANA or ARQT?

Do analysts prefer SANA or ARQT?

Do insiders & institutionals hold more shares of SANA or ARQT?

Does the media prefer SANA or ARQT?

Which has more risk & volatility, SANA or ARQT?

Summary

How does Sana Biotechnology compare to Dyne Therapeutics?

Is DYN or SANA more profitable?

Which has more volatility and risk, DYN or SANA?

Which has preferable valuation & earnings, DYN or SANA?

Does the media refer more to DYN or SANA?

Do insiders and institutionals have more ownership in DYN or SANA?

Do analysts recommend DYN or SANA?

Summary

How does Sana Biotechnology compare to Structure Therapeutics?

Which has better valuation & earnings, SANA or GPCR?

Does the media refer more to SANA or GPCR?

Which has more risk & volatility, SANA or GPCR?

Do analysts prefer SANA or GPCR?

Do insiders & institutionals hold more shares of SANA or GPCR?

Is SANA or GPCR more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SANA vs. The Competition

Sana Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools